To mention, the second generation ALK inhibitor ceritinib showed a synergistic effect with PD-1/PD-L1 blockade to provide an improved anti-tumor response along with favorable side effect tolerability in vivo NSCLC xenograft model (9) and clinical trial (10). This evidence concerns the gene ALK and neoplasm.